Accounts Receivable, after Allowance for Credit Loss, Current of Y-mAbs Therapeutics, Inc. from 31 Mar 2021 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
Y-mAbs Therapeutics, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD history and change rate from 31 Mar 2021 to 30 Jun 2025.
  • Y-mAbs Therapeutics, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 30 Jun 2025 was $15,740,000, a 29% decline year-over-year.
Source SEC data
View on sec.gov
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Change (%)

Y-mAbs Therapeutics, Inc. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $15,740,000 -$6,451,000 -29% 30 Jun 2025 10-Q 08 Aug 2025 2025 Q2
Q1 2025 $17,740,000 -$2,848,000 -14% 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $19,688,000 -$2,766,000 -12% 31 Dec 2024 10-Q 08 Aug 2025 2025 Q2
Q3 2024 $19,916,000 +$1,042,000 +5.5% 30 Sep 2024 10-Q 08 Nov 2024 2024 Q3
Q2 2024 $22,191,000 +$3,073,000 +16% 30 Jun 2024 10-Q 12 Aug 2024 2024 Q2
Q1 2024 $20,588,000 +$1,886,000 +10% 31 Mar 2024 10-Q 07 May 2024 2024 Q1
Q4 2023 $22,454,000 +$9,923,000 +79% 31 Dec 2023 10-K 04 Mar 2025 2024 FY
Q3 2023 $18,874,000 +$9,623,000 +104% 30 Sep 2023 10-Q 13 Nov 2023 2023 Q3
Q2 2023 $19,118,000 +$11,910,000 +165% 30 Jun 2023 10-Q 10 Aug 2023 2023 Q2
Q1 2023 $18,702,000 +$9,378,000 +101% 31 Mar 2023 10-Q 08 May 2023 2023 Q1
Q4 2022 $12,531,000 +$4,819,000 +62% 31 Dec 2022 10-K 29 Feb 2024 2023 FY
Q3 2022 $9,251,000 +$1,987,000 +27% 30 Sep 2022 10-Q 07 Nov 2022 2022 Q3
Q2 2022 $7,208,000 -$1,309,000 -15% 30 Jun 2022 10-Q 08 Aug 2022 2021 Q3
Q1 2022 $9,324,000 +$3,327,000 +55% 31 Mar 2022 10-Q 09 May 2022 2022 Q1
Q4 2021 $7,712,000 31 Dec 2021 10-K 30 Mar 2023 2022 FY
Q3 2021 $7,264,000 30 Sep 2021 10-Q 04 Nov 2021 2021 Q3
Q2 2021 $8,517,000 30 Jun 2021 10-Q 09 Aug 2021 2021 Q2
Q1 2021 $5,997,000 31 Mar 2021 10-Q 06 May 2021 2021 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.